Articles Archive - Page 314 of 322

Survey Highlights High Out-of-pocket Costs for RA Care

Richard Quinn | October 25, 2013

The “RA in America 2013″ survey estimates out-of-pocket cost for RA treatment at $1,000 to $5,000 per year. (posted Oct. 25)

Medicare Participation Numbers Don’t Tell the Whole Story

Richard Quinn | October 16, 2013

Although HHS reports no significant changes in Medicare participation for office-based physicians, the numbers may be misleading. (posted Oct. 16, 2013)

Telomere Length Provides Insights into Cartilage Aging and Repair

Lara C. Pullen, PhD | October 8, 2013

Chondrocyte telomere length might play a role in the natural aging of cartilage, as well as the development and progression of OA. (posted Oct. 8, 2013)

Study Points to Need for Increased Antirheumatic Therapy in Patients with Dyslipidemia

Lara C. Pullen, PhD | October 4, 2013

A new study suggests that patients diagnosed with RA as well as dyslipidemia may benefit from more aggressive antirheumatic therapy. (posted Oct. 3, 2013)

Supreme Court Decision on Gene Patents Good News for Clinicians, Researchers

Richard Quinn | September 24, 2013

The recent U.S. Supreme Court decision that ruled human genes cannot be patented may provide greater access to genetic testing. (posted Sept. 24, 2013)

Lactoferricin’s Role in Preventing Disc Degeneration

Lara C. Pullen, PhD | September 16, 2013

The combination of bone-morphogenetic protein-7 (BMP7) and lactoferricin B (LfcinB) may be a useful treatment for disc degeneration. (posted Sept. 16, 2013)

Sensory Nerves May Be Key for Osteoporosis

Lara C. Pullen, PhD | September 10, 2013

Sensory nerves have an essential role in bone remodeling. In particular, semaphorin 3A (Sema3A) regulates bone remodeling by modulating sensory nerve development. (posted Sept. 9, 2013)

Speak Out Rheum: Under the Radar

Sarah Schafer, MD | September 10, 2013

A physician–patient’s experience with Sjögren’s syndrome

SGR Fix Finally on the Horizon?

Richard Quinn | September 10, 2013

By a 51–0 vote, the House Energy and Commerce Committee in July passed H.R. 2810, legislation that would repeal the Sustainable Growth Rate (SGR) formula. (posted Sept. 9, 2013)

RA Treatment Options Expanded with New Infusible TNF Inhibitor

Richard Quinn | August 21, 2013

FDA approves second infusible anti–tumor necrosis factor treatment for patients with moderate to severe rheumatoid arthritis. (posted Aug. 16, 2013)